Literature DB >> 2569358

Chromosome 12q heterozygosity is retained in i(12p)-positive testicular germ cell tumor cells.

A Geurts van Kessel1, E van Drunen, B de Jong, J W Oosterhuis, A Langeveld, M P Mulder.   

Abstract

Restriction fragment length polymorphism analysis is used to demonstrate that formation of the i(12p) chromosome, characteristic of testicular germ cell tumors, does not lead to loss of heterozygosity of various loci on the q arm of chromosome 12. This result suggests that during the etiology of these tumors, aneuploidization precedes the formation of the i(12p) marker chromosome.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2569358     DOI： 10.1016/0165-4608(89)90154-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN： 0165-4608


  5 in total

1.  Demonstration of the genuine iso-12p character of the standard marker chromosome of testicular germ cell tumors and identification of further chromosome 12 aberrations by competitive in situ hybridization.

Authors:  R F Suijkerbuijk; A Y van de Veen; J van Echten; C H Buys; B de Jong; J W Oosterhuis; D A Warburton; J J Cassiman; D Schonk; A Geurts van Kessel
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

Review 2.  Human germ cell tumours from a developmental perspective.

Authors:  J Wolter Oosterhuis; Leendert H J Looijenga
Journal:  Nat Rev Cancer       Date:  2019-08-14       Impact factor: 60.716

3.  Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults.

Authors:  B Summersgill; P Osin; Y J Lu; R Huddart; J Shipley
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

4.  Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Authors:  Hui Shen; Juliann Shih; Daniel P Hollern; Linghua Wang; Reanne Bowlby; Satish K Tickoo; Vésteinn Thorsson; Andrew J Mungall; Yulia Newton; Apurva M Hegde; Joshua Armenia; Francisco Sánchez-Vega; John Pluta; Louise C Pyle; Rohit Mehra; Victor E Reuter; Guilherme Godoy; Jeffrey Jones; Carl S Shelley; Darren R Feldman; Daniel O Vidal; Davor Lessel; Tomislav Kulis; Flavio M Cárcano; Kristen M Leraas; Tara M Lichtenberg; Denise Brooks; Andrew D Cherniack; Juok Cho; David I Heiman; Katayoon Kasaian; Minwei Liu; Michael S Noble; Liu Xi; Hailei Zhang; Wanding Zhou; Jean C ZenKlusen; Carolyn M Hutter; Ina Felau; Jiashan Zhang; Nikolaus Schultz; Gad Getz; Matthew Meyerson; Joshua M Stuart; Rehan Akbani; David A Wheeler; Peter W Laird; Katherine L Nathanson; Victoria K Cortessis; Katherine A Hoadley
Journal:  Cell Rep       Date:  2018-06-12       Impact factor: 9.423

5.  Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors.

Authors:  Bijun Lian; Wenhui Zhang; Tiegong Wang; Qingsong Yang; Zepeng Jia; Huan Chen; Lei Wang; Jing Xu; Wei Wang; Kai Cao; Xu Gao; Yinghao Sun; Chengwei Shao; Zhiyong Liu; Jing Li
Journal:  Oncologist       Date:  2019-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.